Aurigon
Aurigon is a trusted partner in drug development, offering innovative preclinical services with a focus on quality, agility, scientific solutions, and customization. Established in 2000, it provides comprehensive advisory and experimental services in pharmacology, bioanalytics, and toxicology, supporting pharmaceutical, chemical, food, and biotech industries worldwide. With headquarters in Munich and a state-of-the-art research center in Budapest, Aurigon emphasizes good science and animal welfare, aiming to keep its clients a wingstroke ahead in the industry.
Industries
Nr. of Employees
medium (51-250)
Services
Custom packages covering study conception, protocol development, execution of in vivo and in vitro studies, and interpretation of results.
Regulatory-grade toxicology studies and late-stage testing to support submission requirements.
Analytical measurement of biological endpoints, biomarker quantification and method support for pharmacology and toxicology studies.
Consultancy from study conception through reporting, including protocol development, project management and regulatory-relevant interpretation.
Collaboration in multi-partner research initiatives, joint projects and academic partnerships to advance translational research.
Custom packages covering study conception, protocol development, execution of in vivo and in vitro studies, and interpretation of results.
Regulatory-grade toxicology studies and late-stage testing to support submission requirements.
Analytical measurement of biological endpoints, biomarker quantification and method support for pharmacology and toxicology studies.
Consultancy from study conception through reporting, including protocol development, project management and regulatory-relevant interpretation.
Collaboration in multi-partner research initiatives, joint projects and academic partnerships to advance translational research.
Expertise Areas
- Preclinical drug development
- Regulatory toxicology
- Pharmacology
- Bioanalytical testing
Key Technologies
- GLP/GMP-compliant laboratory operations
- In vivo animal models
- In vitro assay platforms
- Bioanalytical assays
News & Updates
Aurigon is attending Bio Korea 2025, happening from May 7-9 in Seoul. The company is represented by Sigrid Messemer, Senior BD Manager, and Dr. István Gacsályi, CEO. The event is an opportunity to expand potential partnerships in the Asian market.
Aurigon signed a cooperation agreement with the Department of Pharmaceutical Technology at the University of Debrecen Hungary. The partnership will offer internship opportunities, guest lectures, and collaborative initiatives for the faculty.
Aurigon Group completed a corporate reorganization, branding the group Aurigon Labs, and a financial restructuring to strengthen its balance sheets and position for further growth. The company emphasizes Hungary's conducive environment for research and its strategic positioning to leverage talents and deliver innovative solutions.
Aurigon launched the NEXGEN-PD research initiative in April 2023, involving researchers from Austria, Hungary, France, Germany, and the Netherlands. The project aims to develop early diagnostic assays and vaccines to halt Parkinson’s Disease progression.
Tamas Kitka, a colleague of Aurigon, co-authored a paper published in NeuroImage: Clinical, showing that early alterations in fMRI food cue reactivity can predict weight loss outcomes in obese patients.
Aurigon highlights the EMA's publication of a booklet titled 'From laboratory to patient: the journey of a centrally authorised medicine,' providing an overview of the drug development process.
Aurigon is attending Bio Korea 2025, happening from May 7-9 in Seoul. The company is represented by Sigrid Messemer, Senior BD Manager, and Dr. István Gacsályi, CEO. The event is an opportunity to expand potential partnerships in the Asian market.
Aurigon signed a cooperation agreement with the Department of Pharmaceutical Technology at the University of Debrecen Hungary. The partnership will offer internship opportunities, guest lectures, and collaborative initiatives for the faculty.
Aurigon Group completed a corporate reorganization, branding the group Aurigon Labs, and a financial restructuring to strengthen its balance sheets and position for further growth. The company emphasizes Hungary's conducive environment for research and its strategic positioning to leverage talents and deliver innovative solutions.
Aurigon launched the NEXGEN-PD research initiative in April 2023, involving researchers from Austria, Hungary, France, Germany, and the Netherlands. The project aims to develop early diagnostic assays and vaccines to halt Parkinson’s Disease progression.
Tamas Kitka, a colleague of Aurigon, co-authored a paper published in NeuroImage: Clinical, showing that early alterations in fMRI food cue reactivity can predict weight loss outcomes in obese patients.
Aurigon highlights the EMA's publication of a booklet titled 'From laboratory to patient: the journey of a centrally authorised medicine,' providing an overview of the drug development process.